Physician profile
Shearin Higgs
NPI 1740258896
$3,588.59
in general payments reported to CMS, 2019-2025
31 companies · $648 in 2025
The $648 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $15.65 · 2021: $54.05 · 2022: $599 · 2023: $949 · 2024: $1,062 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $559.20 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $535.16 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $468.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $364.32 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $196.24 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $148.91 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $144.05 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.02 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $97.88 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $90.67 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $86.70 | 2022-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $84.35 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $65.99 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.06 | 2023 | |
| Baxter Healthcare | $55.56 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.43 | 2023-2024 | Verquvo, Belsomra, Capvaxive |
| Dexcom, INC. | $49.80 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $47.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $45.99 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $37.22 | 2025 | Interstim |
| Pfizer INC. | $33.79 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $33.66 | 2022 | |
| Ironwood Pharmaceuticals, INC | $29.72 | 2022-2024 | |
| Atland Pharmaceuticals, LLC | $25.44 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Idorsia Pharmaceuticals US INC | $24.81 | 2023 | Quviviq |
| Boston Scientific Corporation | $23.42 | 2024 | |
| Amarin Pharma, INC. | $22.84 | 2021 | |
| Hologic Sales and Service, LLC | $21.76 | 2024 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.13 | 2024 | Xifaxan |
| Global Blood Therapeutics, INC. | $12.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shearin Higgs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.